Malignant Mesothelioma Market Outlook

Thelansis’s “Malignant Mesothelioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Malignant Mesothelioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Malignant Mesothelioma Overview

Malignant mesothelioma is a rare form of cancer arising from the mesothelial cells that line various viscera. It is primarily associated with asbestos exposure and is observed in the pleural lining (malignant pleural mesothelioma). The exact mechanisms by which asbestos exposure leads to the development of malignant mesothelioma are not fully understood but are believed to involve repeated pleural inflammation, interference with cell division, activation of proto-oncogenes, and oxidative stress. The three histological subtypes of mesothelioma are epithelioid, sarcomatoid, and mixed, with the epithelioid subtype associated with a better prognosis. Malignant pleural mesothelioma spreads locally, initially affecting the parietal pleura and then spreading to the visceral pleura, chest wall, diaphragm, or mediastinum. Direct invasion of regional lymph nodes, particularly the bronchopulmonary or hilar nodes, is also observed. The initial symptoms of malignant pleural mesothelioma are usually vague and atypical, including abdominal pain, distension, weight loss, anorexia, and ascites. The differential diagnosis for this condition includes several other lung cancers, benign pleural masses, and lung infections. Multiple factors, including the presentation stage, gender, and the extent of surgical resection, influence the prognosis of malignant pleural mesothelioma. Patients who underwent successful surgical resection have a significantly better prognosis, with longer median survival and higher 5-year survival rates.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)